Published in World J Hepatol on March 27, 2010
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol (2014) 0.83
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Chronic hepatitis B. Hepatology (2007) 13.75
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology (2008) 2.95
Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther (2008) 2.90
HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology (2008) 2.84
Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med (2001) 2.57
High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol (2008) 2.56
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (1999) 2.16
Liver transplantation for hepatocellular carcinoma. Gastroenterology (2005) 2.15
Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol (1996) 1.79
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther (2007) 1.76
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med (2009) 1.72
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 1.52
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol (2001) 1.39
Screening for hepatocellular carcinoma in cirrhosis. J Hepatol (2003) 1.27
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer (1998) 1.10
Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer (1998) 1.06
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat (2009) 1.06
Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1997) 1.04
Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol (1997) 1.00
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat (2004) 0.92
Combination treatment in HBeAg-negative chronic hepatitis B. World J Hepatol (2009) 0.75